Among insulinotropic compounds used in the treatment of T2DM, the administration of which is known to have a beneficial effect on the brain energy expenditure, incretin-based drugs deserve special attention, namely because they act by enhancing or mimicking the action of endogenous incretin hormone glucagon-like peptide-1 (GLP-1). The gene discussed is GCG; the disease is type 2 diabetes mellitus.